Etanercept– 50 mg as a subcutaneous injection once weekly. Etanercept is a dimeric p75 TNF-alpha receptor Fc fragment fusion protein that binds TNF. An initial dose of 50 mg twice weekly for the first three months of therapy may be used in patients requiring treatment for moderate to severe psoriatic skin disease.

Infliximab– 5 mg/kg administered by intravenous infusion at zero, two, and six weeks, followed by 5 mg/kg every eight weeks thereafter. It may be given either with or without MTX. Infliximab is a human / mouse chimeric anti-TNF-alpha antibody.

Adalimumab 40 mg subcutaneously once every two weeks. Adalimumab is a human monoclonal anti-TNF antibody.

●Golimumab 50 mg subcutaneously once monthly. Golimumab is a human monoclonal anti-TNF antibody.

●Certolizumab pegol: nitial dose of 400 mg (administered as two 200 mg injections subcutaneously), with this dose repeated two and four weeks after the initial dose; maintenance with 200 mg once every other week, but may alternatively treat with 400 mg every four weeks. Certolizumab pegol is a pegylated Fab fragment of a humanized anti-TNF monoclonal antibody.